Division of Abbott Laboratories Inc.
Latest From Wampole Laboratories
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Abbott Laboratories Inc.
- Senior Management
John Bridgen, PhD, Pres.
Christina Utz, VP, Licensing and R & D
- Contact Info
Phone: (609) 443-7100
Half Acre Rd.
P.O. Box 1001 Cranbury, NJ 08512
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.